Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Teva
Cantor Fitzgerald
QuintilesIMS
Julphar
Chinese Patent Office
US Department of Justice
McKesson
Fish and Richardson

Generated: May 25, 2018

DrugPatentWatch Database Preview

Cevimeline hydrochloride - Generic Drug Details

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for cevimeline hydrochloride and what is the scope of cevimeline hydrochloride freedom to operate?

Cevimeline hydrochloride
is the generic ingredient in two branded drugs marketed by Apotex Inc, Novel Labs Inc, Rising Pharms Inc, West-ward Pharms Int, and Daiichi Sankyo Inc, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for cevimeline hydrochloride. Nine suppliers are listed for this compound.
Pharmacology for cevimeline hydrochloride

US Patents and Regulatory Information for cevimeline hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Daiichi Sankyo Inc EVOXAC cevimeline hydrochloride CAPSULE;ORAL 020989-002 Jan 11, 2000 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Rising Pharms Inc CEVIMELINE HYDROCHLORIDE cevimeline hydrochloride CAPSULE;ORAL 203775-001 Jun 4, 2014 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Apotex Inc CEVIMELINE HYDROCHLORIDE cevimeline hydrochloride CAPSULE;ORAL 091260-001 Aug 25, 2011 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
West-ward Pharms Int CEVIMELINE HYDROCHLORIDE cevimeline hydrochloride CAPSULE;ORAL 091591-001 Jul 8, 2013 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for cevimeline hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Daiichi Sankyo Inc EVOXAC cevimeline hydrochloride CAPSULE;ORAL 020989-002 Jan 11, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Daiichi Sankyo Inc EVOXAC cevimeline hydrochloride CAPSULE;ORAL 020989-002 Jan 11, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Daiichi Sankyo Inc EVOXAC cevimeline hydrochloride CAPSULE;ORAL 020989-002 Jan 11, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Chubb
Fuji
QuintilesIMS
Teva
UBS
Johnson and Johnson
Fish and Richardson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.